Physician

Christopher Alexander, DO

According to 2025 Medicare claims, Christopher Alexander, DO (NPI: 1306850508) practices hematology/oncology in the Deltona-Daytona Beach-Ormond Beach, FL market, with the plurality of this provider's patient population coming from Volusia, FL. This provider's primary affiliated billing organization is FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (NPI: 1760590962; TIN: 65-0825133) and primary practice location at 32174-8179. Alexander is affiliated with the Complete Health Accountable Care LLC (ACO ID: D0036), participating under the REACH model.

Alexander's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 991 traditional Medicare patients, billed 319,570 HCPCS/CPT codes, and received $4,847,489 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 2,637 prescription claims across 383 beneficiaries totaling $6,553,579 in drug costs, led by Revlimid (Lenalidomide). DME data shows 60 claims. Open Payments data shows 127 records totaling $2,591. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $2,895,455 to $4,847,489. Similarly, Part D prescription costs have moved from a lower plateau to a higher plateau, from $2,348,976 to $6,553,579. In contrast, DME billing represents a smaller volume and moved up and down with repeated peaks and valleys, starting at $2,588 and ending at $3,892.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	949	198,893	$2,895,455
2016	952	223,767	$3,282,927
2017	1,131	226,712	$3,709,564
2018	1,198	280,719	$4,458,286
2019	1,328	340,845	$5,104,374
2020	1,302	309,962	$4,986,593
2021	1,385	313,995	$4,138,832
2022	1,139	285,564	$4,195,163
2023	1,042	310,806	$4,710,297
2024	991	319,570	$4,847,489

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	260	1,863	$2,348,976
2016	265	1,890	$2,329,674
2017	298	1,878	$2,689,921
2018	314	2,288	$3,527,430
2019	314	2,089	$3,502,573
2020	306	1,992	$4,377,581
2021	325	2,266	$5,308,587
2022	361	2,503	$6,345,504
2023	401	2,620	$6,183,831
2024	383	2,637	$6,553,579

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	13	157	$61,829
2016	35	134	$64,621
2017	N/R	129	$35,297
2018	N/R	69	$8,712
2019	N/R	87	$8,825
2020	N/R	103	$7,219
2021	N/R	124	$8,095
2022	N/R	67	$2,757
2023	N/R	54	$6,822
2024	N/R	60	$1,258

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	452	1,212	$94
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	299	402	$63
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	311	606	$13
36415	Insertion of needle into vein for collection of blood sample	797	2,645	$9
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	775	2,699	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Revlimid	Lenalidomide	120	3,353	$2,105,466
Brukinsa	Zanubrutinib	58	1,740	$845,162
Ninlaro	Ixazomib Citrate	39	1,092	$495,057
Calquence	Acalabrutinib Maleate	29	870	$433,314
Jakafi	Ruxolitinib Phosphate	16	480	$263,663

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J8521	Capecitabine, oral, 500 mg	N	N/R	30	$920
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	30	$339

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	127	$2,591	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	0	$0	N/R
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Christopher Alexander, DO?

Tedicare shows public-source Medicare data for Christopher Alexander, DO (NPI 1306850508), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Christopher Alexander, DO have ACO affiliation data?

Christopher Alexander, DO is shown with ACO affiliation data for Complete Health Accountable Care LLC (REACH, ACO ID D0036).

What billing organization is linked to Christopher Alexander, DO?

Christopher Alexander, DO is linked to FLORIDA CANCER SPECIALISTS & RESEARCH INSTITUTE, LLC (billing NPI 1760590962) in the available physician profile data.

Does Christopher Alexander, DO have Open Payments data?

Christopher Alexander, DO has 127 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.